$50 Million

Ovid Therapeutics

Follow-on Offering

Lead Left Bookrunner, August 2020

Ovid Therapeutics

Ovid Therapeutics Inc. is a clinical stage biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain. The Company’s most clinically-advanced product candidate, OV101, is a first-in-class δ-selective GABAA receptor agonist. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company for the potential treatment of rare developmental and epileptic encephalopathies (DEE). ovi